OHE

Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis

Retrieved on: 
Thursday, March 28, 2024
OHE, Week, Cirrhosis, Patient, Mitt, NDA, MOA, File, Stage 2, SMI, Recurrence, FDA

SALT LAKE CITY, March 28, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company today announced positive topline results from a Phase 2 clinical study of LPCN 1148.

Key Points: 
  • SALT LAKE CITY, March 28, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company today announced positive topline results from a Phase 2 clinical study of LPCN 1148.
  • LPCN 1148 is targeted to be a "First in Class" product candidate with a novel mechanism of action (MOA).
  • This Phase 2 proof of concept study was a randomized placebo-controlled study in sarcopenic male patients with cirrhosis on the liver transplant waitlist.
  • During Stage 2, 8 participants who were on placebo in Stage 1 converted to LPCN 1148, and 11 participants who started the study on LPCN 1148 continued treatment with LPCN 1148.

Axcella Announces Program Reprioritization and Corporate Restructuring

Retrieved on: 
Thursday, December 15, 2022
Health, Infectious Diseases, COVID-19, Clinical Trials, Pharmaceutical, Biotechnology, Biotechnology, Therapy, Security (finance), COVID-19, Homeostasis, Recurrence, Fatigue, IND, Regulation, Patient, Science, NASH, COVID, Non-alcoholic fatty liver disease, File, Compte rendu, Disclosure, Disease, FDA, Emms, FAQ, Hinshaw, Risk, Clinical trial, LSM, Safety, Regulation Fair Disclosure, OHE, EMM, Pharmaceutical industry, Long COVID

Axcella will reprioritize its efforts to focus on the significant unmet need and opportunity presented by Long COVID.

Key Points: 
  • Axcella will reprioritize its efforts to focus on the significant unmet need and opportunity presented by Long COVID.
  • Axcella is engaged in ongoing and productive reviews with regulators in the U.S. and Europe, and the company is aiming to advance its Long COVID Fatigue program into a potential registration trial.
  • Axcella will be discontinuing its ongoing Phase 2b clinical trial of AXA1125 in NASH, while keeping the option to revisit this program should resource availability change.
  • In September, Axcella reported positive data from a preplanned interim analysis from their trial of AXA1125 in NASH.

India Off-highway Equipment (OHE) Market Analysis/Opportunities Report 2022-2030: Surge in the Mechanization of Processes, Demand for Rental and Leasing Models, Proliferation of Telematics - ResearchAndMarkets.com

Retrieved on: 
Friday, December 9, 2022
Manufacturing, Machinery, Lubricant, Health, Sale, Farmer, OHE, Growth, Online shopping

The increasing sale of aftermarket spares and lubricants through online marketplaces will also lead to the seamless sale of used equipment, with a win-win model for both buyers and sellers.

Key Points: 
  • The increasing sale of aftermarket spares and lubricants through online marketplaces will also lead to the seamless sale of used equipment, with a win-win model for both buyers and sellers.
  • B2B eCommerce and marketplace sites allow stakeholders to buy, rent, sell, auction, and perform various activities related to equipment sourcing.
  • Market participants are beginning to understand telematics' advantages, and the technology is set to capture the Indian market over the next 10 years.
  • In addition, the increased productivity of machine-based processes is increasing the demand for off-highway equipment and agricultural tractors.

Axcella to Present at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting

Retrieved on: 
Thursday, November 3, 2022
Nursing, Biotechnology, Other Health, Health, General Health, Pharmaceutical, Research, Infectious Diseases, Genetics, Science, Clinical Trials, Booth, Disclosure, File, Homeostasis, Research, Recurrence, U.S. Securities and Exchange Commission, EMM, OHE, NASH, Biomarker, American Association for the Study of Liver Diseases, IND, Gastroenterology, Therapy, Institute of Liver and Biliary Sciences, Plasma, AASLD, Metabolism, Transplant, Review, Securities Act of 1933, FAQ, Annual general meeting, Liver disease, Risk, Anesthesiology, Surgeon, Radiology, Security (finance), American Association, Emms, Regulation, Association, Treatment, Patient, Regulation Fair Disclosure, Pharmaceutical industry, Medical imaging, Long COVID

With 8,000 attendees The Liver Meeting is the worlds premier meeting on liver disease.

Key Points: 
  • With 8,000 attendees The Liver Meeting is the worlds premier meeting on liver disease.
  • The information that we post on our website could be deemed to be material information.
  • Axcella is a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using compositions of endogenous metabolic modulators (EMMs).
  • The companys unique model allows for the evaluation of its EMM compositions through non-IND clinical studies or IND clinical trials.

Axcella Announces Completion of Enrollment of Clinical Trial for Long COVID and Has Prioritized its Clinical Portfolio

Retrieved on: 
Thursday, May 26, 2022
Health, Diabetes, Infectious Diseases, General Health, Clinical Trials, Pharmaceutical, Biotechnology, FAQ, Risk, U.S. Securities and Exchange Commission, Regulation Fair Disclosure, Company, Disease, Private Securities Litigation Reform Act, NASH, Disclosure, Patient, File, Review, Therapy, Emms, COVID-19, Fatty liver disease, Regulation, FDA, Securities Act of 1933, Recurrence, IND, Partnership, Program, John Radcliffe Hospital, Safety, Compte rendu, EMM, British Heart Foundation, Degenerative disease, SEC, COVID, Security (finance), Fatigue, University of Oxford, CEO, Pharmaceutical industry, OHE, Long COVID

The company is suspending its Phase 2 clinical trial in OHE (Overt Hepatic Encephalopathy) while exploring potential partnership for the program.

Key Points: 
  • The company is suspending its Phase 2 clinical trial in OHE (Overt Hepatic Encephalopathy) while exploring potential partnership for the program.
  • Patient enrollment is complete in the prospective, placebo controlled, randomized trial conducted at the John Radcliffe Hospital at Oxford University in England.
  • We look forward to sharing the results of the trial given the ever growing patient need for a product to address Long COVID fatigue.
  • Bill Hinshaw, President and CEO of Axcella, continued: We are a leader in therapeutics for Long COVID and in particular addressing fatigue.

Axcella Therapeutics to Participate in the H.C. Wainwright Global Investment Conference

Retrieved on: 
Thursday, May 19, 2022
Health, Diabetes, Infectious Diseases, General Health, Clinical Trials, Pharmaceutical, Biotechnology, FAQ, Risk, U.S. Securities and Exchange Commission, Regulation Fair Disclosure, OHE, NASH, Disclosure, Homeostasis, File, Review, Emms, Investor, Regulation, Securities Act of 1933, Recurrence, IND, EMM, Security (finance), Pharmaceutical industry, Long COVID

The conference call webcast will be accessible in the Investors & News section on the companys website at www.axcellatx.com .

Key Points: 
  • The conference call webcast will be accessible in the Investors & News section on the companys website at www.axcellatx.com .
  • An archive of the webcast replay will be available on the Companys website for up to 90 days.
  • Such disclosures include, but may not be limited to, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, and public conference calls and webcasts.
  • Axcella is a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using compositions of endogenous metabolic modulators (EMMs).

Premium Audio Company, LLC Comments on Onkyo Home Entertainment Bankruptcy Filing

Retrieved on: 
Monday, May 16, 2022
Engineering, OHE, Magnate, Schneider Electric, VOXX, TEAC Corporation, Jamo, Promedia Verlag, Fidelity Investments, NASDAQ, Solution, Sharp, Bankruptcy, Pioneer Corporation, Marketing, Rumor, Integra, Intellectual property, Electronics, Klipsch Audio Technologies, Trading company, PAC, Pioneer, Acquisition, LLC, Sharp Corporation, Music, Western esotericism, Mirage, Onkyo

INDIANAPOLIS, May 16, 2022 /PRNewswire/ -- Premium Audio Company, LLC, ("PAC") a wholly owned subsidiary of VOXX International Corporation (NASDAQ: VOXX), today provided comments regarding Onkyo Home Entertainment Corporation's ("OHE") bankruptcy filing with the Osaka District Court. PAC's statement was made in response to misleading media reports regarding the Onkyo brand, which was acquired through a joint venture between PAC and Sharp Corporation in September 2021 and has grown considerably since.

Key Points: 
  • INDIANAPOLIS, May 16, 2022 /PRNewswire/ -- Premium Audio Company, LLC, ("PAC") a wholly owned subsidiary of VOXX International Corporation (NASDAQ: VOXX), today provided comments regarding Onkyo Home Entertainment Corporation's ("OHE") bankruptcy filing with the Osaka District Court.
  • The Premium Audio Company, through its 11 Trading Company ("11TC") subsidiary, began as a distributor of the Onkyo, Integra, Pioneer and Pioneer Elite brands in July 2020.
  • Established in 2020, Premium Audio Company is the most innovative, complete, and premium audio solutions provider in consumer technology.
  • Premium Audio Company is comprised of three subsidiaries and includes some of the most legendary and revered brands such as Klipsch, Jamo, Mirage, ProMedia, Magnat, Heco, Mac Audio, Onkyo, Pioneer, Pioneer Elite, Integra, Teac, and Esoteric.

Axcella Reports First Quarter Financial Results and Provides Business Update

Retrieved on: 
Thursday, May 5, 2022
Health, Diabetes, Infectious Diseases, General Health, Clinical Trials, Pharmaceutical, Biotechnology, D, COVID-19, Private Securities Litigation Reform Act, Regulation Fair Disclosure, File, IND, Compte rendu, Emms, Regulation, Securities Act of 1933, Physician, Research, Disclosure, Patient, Security (finance), Review, Recurrence, FDA, FAQ, U.S. Securities and Exchange Commission, NASH, Fatty liver disease, EMM, SEC, Homeostasis, OHE, Risk, Therapy, Pharmaceutical industry, Long COVID

Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced financial results for the first quarter ended March 31, 2022 and provided a business update.

Key Points: 
  • Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced financial results for the first quarter ended March 31, 2022 and provided a business update.
  • Axcella expects that its current cash balance will be sufficient to meet its operating needs into 2023.
  • Net Loss: Net loss for the quarter ended March 31, 2022 was $19.0 million, or $0.46 per basic and diluted share.
  • Axcella is a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using compositions of endogenous metabolic modulators (EMMs).

Axcella Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, March 30, 2022
Health, Infectious Diseases, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, 808, Private Securities Litigation Reform Act, Risk, Therapy, Recurrence, Non-alcoholic fatty liver disease, Regulation, Fast Track, Fatty liver disease, Leadership, University, D, Investor, United Kingdom, Fatigue, IND, OHE, SEC, EMM, Institute of Liver and Biliary Sciences, Research, American Association, Enrollment, Telephone, Food, Homeostasis, Security (finance), NASH, Association, Safety, Review, Annual general meeting, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, FAQ, Securities Act of 1933, Disclosure, COVID-19, U.S. Securities and Exchange Commission, Compte rendu, Drug, Regulation Fair Disclosure, AASLD, Cirrhosis, FDA, Patient, File, Emms, Pharmaceutical industry, Dietary supplement

Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced financial results for the fourth quarter and full year ended December 31, 2021 and provided a business update.

Key Points: 
  • Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced financial results for the fourth quarter and full year ended December 31, 2021 and provided a business update.
  • A data-rich period is now fast approaching, with both our Long COVID Phase 2a top-line results and NASH Phase 2b interim results anticipated in the third quarter.
  • Mr. Crane brings to Axcella over 35 years of experience building therapeutics, diagnostics and medical device companies.
  • R&D Expenses: Research and development expenses for the quarter and year ended December 31, 2021 were $12.5 million and $43.1 million, respectively.

Axcella to Report Fourth Quarter and Year End 2021 Financial Results on March 30, 2022

Retrieved on: 
Wednesday, March 23, 2022
Biotechnology, Pharmaceutical, Health, 808, Risk, Regulation, Therapy, Recurrence, Fatty liver disease, Investor, IND, OHE, EMM, Telephone, Security (finance), NASH, Review, FAQ, Securities Act of 1933, Disclosure, U.S. Securities and Exchange Commission, Regulation Fair Disclosure, File, Emms, Pharmaceutical industry

Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that it plans to report its fourth quarter and year end 2021 financial results and other business updates on March 30, 2022.

Key Points: 
  • Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that it plans to report its fourth quarter and year end 2021 financial results and other business updates on March 30, 2022.
  • The conference call webcast will be available in the Investors & News section on the companys website at www.axcellatx.com .
  • For those unable to listen in live, a webcast archive will be available on the companys website for 90 days following the call.
  • Axcella is a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using compositions of endogenous metabolic modulators (EMMs).